Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kimberly West-Osterfield"'
Autor:
Kevin P. Becker, John D. Hainsworth, Tarek Mekhail, David Wright, Howard A. Burris, Sajeel A. Chowdhary, Janice Faulkner Eakle, Kimberly West-Osterfield, Gilbert Darin Anthony Padula, Mythili Shastry, Meredith Scarberry, Kent C. Shih, Robert M. Langdon, Candice A. Shaifer, Kathleen Yost
Publikováno v:
Journal of Neuro-Oncology. 144:303-311
Current bevacizumab-based regimens have failed to improve survival in patients with recurrent glioblastoma. To improve treatment efficacy, we evaluated bevacizumab + BKM120, an oral pan-class I PI3K inhibitor, in this patient population. A brief phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c845679595802fdeb2f9fdd0010e6b21
https://doi.org/10.1007/s11060-019-03227-7
https://doi.org/10.1007/s11060-019-03227-7
Autor:
Zhaoliang Li, Alex Panaccione, Kimberly West-Osterfield, Stephen R. Hann, Erick Spears, Qin Zhang
Publikováno v:
Genes; Volume 8; Issue 5; Pages: 134
Genes
Genes
MYC is a transcription factor that is essential for cellular proliferation and development. Deregulation or overexpression of MYC occurs in a variety of human cancers. Ectopic expression of MYC causes hyperproliferation and transformation of cells in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::427d249bbf99453298ec8fd0b153a1d1
Autor:
Elizabeth R. Vazquez, F. Anthony Greco, Jitendra G. Gandhi, Suzanne F. Jones, John D. Hainsworth, Bobby L. Clark, James D. Peyton, Victor G. Gian, Kimberly West-Osterfield, Howard A. Burris, David R. Spigel
Publikováno v:
Journal of Thoracic Oncology. 5(6):862-866
Background Carboplatin and topotecan are commonly used in the treatment of small cell lung cancer (SCLC); however, there are no data for this combination in the first-line setting using weekly topotecan. In this multicenter, community-based phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96ba74af6eb6274a2feecee4750f1d6
Autor:
Kimberly West-Osterfield, Terrence Cescon, Bobby L. Clark, Dianna Shipley, David R. Spigel, Dana S. Thompson, John D. Hainsworth, C. Farley, Cassie M. Lane, F. Anthony Greco, Martin J. Bury
Publikováno v:
The Cancer Journal. 16:70-75
Purpose To compare the results of empiric first-line therapy with paclitaxel/carboplatin/etoposide (PCE) versus gemcitabine/irinotecan, both followed by single-agent gefitinib, in patients with carcinoma of unknown primary site. Patients and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f64656360cd20d155351c0a68cbde3d3
https://doi.org/10.1097/ppo.0b013e3181c6aa89
https://doi.org/10.1097/ppo.0b013e3181c6aa89